Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

PLoS One · 2016 · PMC5100926 · PMID 27824902

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In lower-risk MDS patients with 5q deletion who received lenalidomide treatment, unmutated TP53 status showed a trend to predict the achievement of HI and CyR [ 35 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.